Clinical Trials | Novartis

Media Release
Aug 28, 2024
Novartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk
Media Release
Apr 23, 2024
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
Story
Feb 14, 2024
Listening to the CML patient community
Story
Dec 12, 2023
Innovation fueled by compassion
Story
Dec 08, 2023
Shoulder to shoulder
Media Release
Nov 20, 2023
Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH
Media Release
Oct 07, 2021
Novartis to present broad range of portfolio data at ECTRIMS, reinforcing long-standing commitment to people living with multiple sclerosis
Media Release
Sep 23, 2020
Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program
Media Release
May 27, 2021
Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19
Media Release
Jun 02, 2021
Novartis presents positive Phase III results from JUNIPERA study supporting Cosentyx® as a potential treatment in a JIA population at EULAR 2021
Media Release
Dec 12, 2019
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Story
Jun 04, 2019
Toward improving the health and longevity of transplanted organs